Europe has the science & talent to lead the next generation of therapeutic innovation. At Institut @Servier's #THRPTX2026, my message was clear: we need to help innovation grow in 🇪🇺, from AI &biotech to improved clinical trials, so the latest therapies reach patients faster.⬇️ https://t.co/AXWXl2nwx5 #TherapeuticInnovation #Biotech #ClinicalTrials
🇪🇺 produces 21% of the world’s leading biotech publications, but our share of global clinical trials fell from 18% to 9%. The #BiotechAct is our answer: faster trials, more investment, clearer rules, stronger incentives for 🇪🇺 manufacturing & better use of health data and AI. #BiotechAct #ClinicalTrials #HealthData #EU
Novo Nordisk's clinical trial for Ziltivekimab, an antibody targeting pro-inflammatory cytokine IL-6, failed 👀 Interestingly, both IL-6 and hsCRP fell with treatment, suggesting an anti-inflammatory effect, yet this did not translate into fewer cardiovascular events. https://t.co/jSZTM1Qxad #NovoNordisk #Ziltivekimab #ClinicalTrials #Nospecificcountriesarementionedinthetweet.
This tragic case is a reminder of why clinical trials and risk-averse regulatory agencies matter. And why unregulated "anti-aging" treatments should concern us all. What the longevity field needs is more rigorous science, not more hype. #ClinicalTrials #AntiAging #LongevityResearch #Therearenospecificcountrymentionsinthetweet #sotherearenocountrycodestoreturn.
True. No ethical analysis appears to have been done before they started this experiment, and no proper clinics studies were performance before the protocol was adopted by the international professional association for trans care and spread across the globe #EthicsInResearch #TransHealthcare #ClinicalTrials #Therearenospecificcountrycodesidentifiedintheprovidedtweet.
"Nearly 7 years after her first attempt to test Ebola prevention drugs, Jaspard is stunned by the sudden interest in the trial. “I've kept this project for all these years, despite the fact that a lot of people were saying it's not useful, you don't need to do this, go away,” she #Ebola #ClinicalTrials #MedicalResearch #Therearenospecificcountryreferencesinthetweetprovided.
In an article by Gina Kolata and Rebecca Robbins, 27 scientists, doctors, and clinical trial participants discuss the groundbreaking potential of daraxonrasib, a drug nearing FDA approval that significantly extends the lives of pancreatic cancer patients by targeting the KRAS protein, marking a significant advancement in cancer treatment after decades of failed experimental therapies. #CancerResearch #PancreaticCancer #ClinicalTrials #USA #MIT #Harvard #NC #MI #CA #NY #EU
The article by Gina Kolata and Rebecca Robbins discusses the groundbreaking development of daraxonrasib, a new drug that has the potential to significantly extend the life of pancreatic cancer patients, overcoming long-held beliefs about the challenges of targeting the KRAS protein, which is implicated in various cancers, thanks to decades of research and innovation in drug development. #CancerResearch #PancreaticCancer #ClinicalTrials #US #CA #EU
Gina Kolata and Rebecca Robbins report on the promising breakthrough of daraxonrasib, a drug that significantly extends the life of pancreatic cancer patients by targeting the KRAS protein, marking a potential turning point in cancer treatment after decades of failed attempts. #CancerResearch #PancreaticCancer #ClinicalTrials #US #CA #EU
An experimental drug, daraxonrasib, developed by Revolution Medicines, has shown promise in nearly doubling survival time for patients with advanced pancreatic cancer during clinical trials, despite a high rate of mostly manageable side effects, according to a recently reported study. #PancreaticCancer #ClinicalTrials #CancerResearch #US #IN
Pam Belluck's article details Amanda Sifford's experience with a new A.L.S. therapy called tofersen, which has shown promising results in improving her lung function and overall health despite the challenges of a severe neurological condition that has afflicted her family. #ALS #Neurology #ClinicalTrials #US #CA
Organizace Alzheimer's Research UK upozorňuje, že pacienti s Alzheimerovou chorobou přicházejí o možnost účasti v klinických studiích kvůli zpožděným nebo nepřesným diagnózám, což může mít za následek, že nebudou mít přístup k novým léčebným možnostem, v době, kdy počet zkoušených léků na tuto nemoc roste. #AlzheimersResearch #ClinicalTrials #DiagnosisChallenges
